Section Arrow
ARGX.NASDAQ
- argenx SE
Quotes are at least 15-min delayed:2026/07/15 07:20 EDT
Pre Market
Last
 861.61
+2.18 (+0.25%)
Bid
860.93
Ask
862.17
High 863.74 
Low 855.8 
Volume 42 
Regular Hours (Closed)
Last
 859.43
-16.82 (-1.92%)
Day High 
879.89 
Prev. Close
876.25 
1-M High
953.58 
Volume 
269.86K 
Bid
860.93
Ask
862.17
Day Low
858.13 
Open
871.04 
1-M Low
837.74 
Market Cap 
54.49B 
Currency 美元 
P/E 38.93 
%Yield -- 
10-SMA 910.48 
20-SMA 895.82 
50-SMA 850.64 
52-W High 953.58 
52-W Low 560.9075 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
22.51/29.46
Enterprise Value
54.53B
Balance Sheet
Book Value Per Share
117.76
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
4.15B
Operating Revenue Per Share
15.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NXTCNextCure Inc6.58+4.4+201.83%-- 
Pre Market 5.08 -1.5 -22.80%
AEONAEON Biopharma0.357+0.0349+10.84%-- 
Pre Market 0.3088 -0.0482 -13.50%
GOSSGossamer Bio0.1401-0.004-2.78%-- 
Pre Market 0.1408 +0.0007 +0.50%
RXRXRecursion Pharmaceuticals3.34+0.04+1.21%-- 
Pre Market 3.37 +0.03 +0.90%
ENSCEnsysce Biosciences0.2925+0.017+6.17%-- 
Pre Market 0.275 -0.0175 -5.98%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.